DGAP-News: CO.DON AG: Spherox available for patients in Switzerland

CO.DON AG - Spherox available for patients in Switzerland

Berlin / Teltow, 03.04.2019 - CO.DON AG has received regulatory approval in Switzerland for its Spherox product, for which it already holds EU-wide marketing authorisation. The price eligible for reimbursement in Switzerland is comparable with the level in the EU.

The first clinics have already expressed a strong interest in working with CO.DON AG and deploying Spherox in Switzerland as quickly as possible.

Ralf Jakobs, CEO of CO.DON AG: "The approval from the Swiss regulatory authorities is great news for us at CO.DON AG. Firstly because it was received ahead of schedule. And secondly because following the existing EU-wide marketing authorisation, it is the first approval for our product outside the EU framework and so is an important milestone in the overall context of our international business strategy.

The costs are already reimbursed in the Swiss market, in contrast to other markets, so we can start distribution of our product here very soon. Here the long-standing presence of our own subsidiary in Switzerland has had a positive effect on our business prospects, because this company means we already have good contacts to the relevant authorities and hospitals."

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 we received marketing authorisation for the advanced therapy medicinal product Spherox from the European Medicines Agency. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.
Further information is available from www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de